Biotech | August 08, 2021
Strides Pharma reports Q1FY22 consolidated loss at Rs 205.2 Cr
The company expects revenue growth of 10-15 per cent in the US
The company expects revenue growth of 10-15 per cent in the US
PAT rises to Rs 195.76 crore
The transaction is expected to close in the Q4FY22
India business contributes to a stellar performance
Forex gains stood at Rs 20 crore for the quarter
India is dependent upon China and other countries for a lot of Key Starting Materials (KSM) for their bulk drug needs.
Ibuprofen and Famotidine Tablets is an AB-rated generic therapeutic equivalent version of Horizon Medicines LLC’s Duexis Tablets, 800 mg/26.6 mg
Advances deployment of mRNA technology across vaccines and therapeutics development
This robust growth has come despite the raging pandemic for most part of the quarter
Subscribe To Our Newsletter & Stay Updated
